HLA expression by benign and malignant prostatic epithelium: augmentation by interferon-gamma.
Chronic prostatitis is a poorly understood entity that is characterized by lymphocytic infiltration of benign prostatic epithelium. Previously, we and others have shown that prostatic epithelium involved by prostatitis is phenotypically different from uninvolved epithelium. In addition, we have shown that malignant prostatic epithelium is rarely, if ever, infiltrated by lymphocytes. We now report that benign prostatic epithelium expresses HLA-DR only in the presence of lymphocytic inflammation, and that benign epithelium without chronic prostatitis and malignant prostatic epithelium do not express HLA-DR. In order to determine whether HLA-DR expression is inducible on malignant prostatic epithelium and therefore, at least theoretically, susceptible to immune regulation, we studied the DU-145 cell line in culture under various conditions. DU-145 cells did not express HLA-DR under routine culture conditions. However, the addition of interferon-gamma (100 to 6000 U/ml.) resulted in HLA-DR expression by DU-145 cells at 24 hours with maximal expression by 72 hours. In contrast, other cytokines (tumor necrosis factor, interleukin-1, interleukin-2) had no effect on HLA-DR expression. These investigations show that interferon-gamma induces HLA-DR expression on the DU-145 prostatic adenocarcinoma cell line, raising the theoretical possibility that malignant prostatic cells may be induced in vivo to express HLA-DR and thus become susceptible to immune regulation.
Blumenfeld
W
W
Department of Anatomic Pathology, Department of Veteran Affairs Medical Center, San Francisco.
Ye
J Q
JQ
Dahiya
R
R
Griffiss
J M
JM
Narayan
P
P
D000230:Adenocarcinoma / Q000276:immunology*; D004848:Epithelium / Q000378:metabolism; D015870:Gene Expression; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000494:pharmacology*; D008297:Male; D011467:Prostate / Q000276:immunology*; D011470:Prostatic Hyperplasia / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000276:immunology*; D011472:Prostatitis / Q000276:immunology*; D014407:Tumor Cells, Cultured
D006684:HLA-DR Antigens; D007371:Interferon-gamma